LUMEA BxChipTM Now Available in European Markets

The groundbreaking LUMEA BxChipTM, which has been recently highlighted in the American Journal of Clinical Pathology for its ability to help pathology labs dramatically reduce cost and increase the efficiency of personnel, is now available in select European markets. The BxChip, which is manufactured in the EU by Themis Pathology, a subsidiary of LUMEA, is supported by market-leading distribution partners.

In the United Kingdom and Ireland, CellPath Ltd. will be offering sales and support for the BxChip at the end of September 2019. CellPath is an independent company attuned to the needs of Cellular Pathology, specializing in the manufacture and worldwide supply of products, consumables, and services to the Histopathology and Cytology markets. For more information, please contact CellPath here or come to the CellPath booth at the upcoming Institute of Biomedical Science Congress in Birmingham, UK Sept 23-25 to learn more about the BxChip.

In the Nordic countries, the BxChip is now available from HistoLab AB. HistoLab is the leading provider of comprehensive solutions for research and clinical laboratories in cell diagnostics in the Nordic countries. HistoLab works with leading suppliers and has extensive experience and knowledge of the industry and products. For more information on how to order the BxChip in Sweden, Denmark, Norway, and Finland please contact HistoLab here.

In Germany, the BxChip is now available from CellNass GmbH, trading under the CellPath name. CellNass is the European market leader for microscope slide and paraffin block archiving, and also supplies innovative laboratory consumables and equipment for the pathology market. For more information on ordering the BxChip in Germany please contact CellNass here.

As the operational and clinical benefits of the BxChip become clear, pathology laboratories worldwide are adopting this innovative product. For availability in your national market, please contact LUMEA here.

LUMEA’s mission is to standardize and improve cancer diagnostics. It developed the first integrated biopsy-to-digital diagnostic platform that improves tissue handling, modernizes the pathology process, and enables the commercialization of diagnostic artificial intelligence. This Lehi, Utah-based company was founded in 2014 by Dr. Matthew O. Leavitt, a Stanford-trained pathologist.

Back to news